MX384423B - Biomarcadores para la respuesta a inhibidores del mejorador del homólogo 2 de zeste (ezh2). - Google Patents
Biomarcadores para la respuesta a inhibidores del mejorador del homólogo 2 de zeste (ezh2).Info
- Publication number
- MX384423B MX384423B MX2016017097A MX2016017097A MX384423B MX 384423 B MX384423 B MX 384423B MX 2016017097 A MX2016017097 A MX 2016017097A MX 2016017097 A MX2016017097 A MX 2016017097A MX 384423 B MX384423 B MX 384423B
- Authority
- MX
- Mexico
- Prior art keywords
- ezh2
- biomarkers
- cancer
- enhancer
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
- G01N2333/91011—Methyltransferases (general) (2.1.1.)
- G01N2333/91017—Methyltransferases (general) (2.1.1.) with definite EC number (2.1.1.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462014594P | 2014-06-19 | 2014-06-19 | |
| PCT/US2015/036677 WO2015196064A1 (en) | 2014-06-19 | 2015-06-19 | Biomarkers for response to ezh2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016017097A MX2016017097A (es) | 2017-05-01 |
| MX384423B true MX384423B (es) | 2025-03-14 |
Family
ID=54936135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016017097A MX384423B (es) | 2014-06-19 | 2015-06-19 | Biomarcadores para la respuesta a inhibidores del mejorador del homólogo 2 de zeste (ezh2). |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20170138946A1 (OSRAM) |
| EP (1) | EP3158086B1 (OSRAM) |
| JP (1) | JP6684230B2 (OSRAM) |
| KR (1) | KR20170020463A (OSRAM) |
| CN (1) | CN106795561B (OSRAM) |
| AU (1) | AU2015276899B2 (OSRAM) |
| BR (1) | BR112016029911A2 (OSRAM) |
| CA (1) | CA2952285A1 (OSRAM) |
| EA (1) | EA036889B1 (OSRAM) |
| ES (1) | ES2870096T3 (OSRAM) |
| IL (1) | IL249443B (OSRAM) |
| MX (1) | MX384423B (OSRAM) |
| SG (2) | SG11201610610YA (OSRAM) |
| WO (1) | WO2015196064A1 (OSRAM) |
| ZA (1) | ZA201608555B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102021642B1 (ko) | 2012-10-15 | 2019-09-16 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| CN108025191A (zh) | 2015-08-24 | 2018-05-11 | Epizyme股份有限公司 | 治疗癌症的方法 |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| JP7336193B2 (ja) * | 2016-02-16 | 2023-08-31 | エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ | 原発性胃腺癌の体細胞プロモーター特性を明らかにするエピゲノムプロファイリング |
| GB201615842D0 (en) * | 2016-09-16 | 2016-11-02 | Ucl Business Plc | Cell death biomarker |
| CN106963765B (zh) * | 2017-03-28 | 2020-04-07 | 上海交通大学医学院附属第九人民医院 | Ezh2抑制剂化合物在制备治疗眼部黑色素瘤的药物中的应用 |
| WO2020247130A1 (en) * | 2019-06-03 | 2020-12-10 | Icahn School Of Medicine At Mount Sinai | Compounds and methods for inhibiting cancers via rest inhibition |
| GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| CN118161615B (zh) * | 2024-03-19 | 2025-08-12 | 山东大学齐鲁医院 | Phf20抑制剂在制备抗皮肤癌药物中的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US548257A (en) | 1895-10-22 | Hay rake and loader | ||
| US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
| WO1992010588A1 (en) | 1990-12-06 | 1992-06-25 | Affymax Technologies N.V. | Sequencing by hybridization of a target nucleic acid to a matrix of defined oligonucleotides |
| US6379897B1 (en) | 2000-11-09 | 2002-04-30 | Nanogen, Inc. | Methods for gene expression monitoring on electronic microarrays |
| US6465611B1 (en) | 1997-02-25 | 2002-10-15 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| US5932422A (en) * | 1997-11-14 | 1999-08-03 | Millennium Pharmaceuticals, Inc. | Modulation of drug resistance via ubiquitin carboxy-terminal hydrolase |
| US6218114B1 (en) | 1998-03-27 | 2001-04-17 | Academia Sinica | Methods for detecting differentially expressed genes |
| US6004755A (en) | 1998-04-07 | 1999-12-21 | Incyte Pharmaceuticals, Inc. | Quantitative microarray hybridizaton assays |
| US6218122B1 (en) | 1998-06-19 | 2001-04-17 | Rosetta Inpharmatics, Inc. | Methods of monitoring disease states and therapies using gene expression profiles |
| US6406921B1 (en) | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
| US6271002B1 (en) | 1999-10-04 | 2001-08-07 | Rosetta Inpharmatics, Inc. | RNA amplification method |
| US7429466B2 (en) | 2000-01-24 | 2008-09-30 | Hypromatrix, Inc | Methods and arrays for detecting biological molecules |
| WO2001055454A1 (en) | 2000-01-28 | 2001-08-02 | Althea Technologies, Inc. | Methods for analysis of gene expression |
| WO2002086168A1 (en) | 2001-04-19 | 2002-10-31 | Ciphergen Biosystems, Inc. | Biomolecule characterization using mass spectrometry and affinity tags |
| WO2003070887A2 (en) | 2002-02-20 | 2003-08-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| AU2001286171B2 (en) | 2001-05-25 | 2008-01-10 | Serono Genetics Institute S.A. | Human CDNAs and proteins and uses thereof |
| US7112408B2 (en) | 2001-06-08 | 2006-09-26 | The Brigham And Women's Hospital, Inc. | Detection of ovarian cancer based upon alpha-haptoglobin levels |
| US20030013208A1 (en) | 2001-07-13 | 2003-01-16 | Milagen, Inc. | Information enhanced antibody arrays |
| EP1425695A2 (en) | 2001-08-13 | 2004-06-09 | Beyong Genomics, Inc. | Method and system for profiling biological systems |
| US20030215858A1 (en) | 2002-04-08 | 2003-11-20 | Baylor College Of Medicine | Enhanced gene expression system |
| WO2003091735A1 (en) | 2002-04-23 | 2003-11-06 | Millipore Corporation | Sample preparation of biological fluids for proteomic applications |
| WO2007001986A2 (en) | 2005-06-20 | 2007-01-04 | Yuling Luo | Methods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations |
| US20110251216A1 (en) | 2010-02-19 | 2011-10-13 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| AU2011298987B2 (en) | 2010-09-10 | 2017-09-28 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| AU2012364924A1 (en) * | 2011-02-16 | 2013-09-12 | Medical University Of Graz | BAP1 mutational analysis in determining susceptibility to, prognosis of, and treatment of melanocytic neoplasia |
| WO2012144220A1 (en) * | 2011-04-22 | 2012-10-26 | Oncotherapy Science, Inc. | Ezh2 as target gene for cancer therapy and diagnosis |
| BR112014007603A2 (pt) * | 2011-09-30 | 2017-06-13 | Glaxosmithkline Llc | métodos de tratamento do câncer |
| HUE042271T2 (hu) | 2012-03-12 | 2019-06-28 | Epizyme Inc | Emberi EZH2 inhibitorai és azok alkalmazási eljárásai |
| KR102021642B1 (ko) | 2012-10-15 | 2019-09-16 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
-
2015
- 2015-06-19 CA CA2952285A patent/CA2952285A1/en not_active Abandoned
- 2015-06-19 KR KR1020177001353A patent/KR20170020463A/ko not_active Abandoned
- 2015-06-19 MX MX2016017097A patent/MX384423B/es unknown
- 2015-06-19 ES ES15809484T patent/ES2870096T3/es active Active
- 2015-06-19 AU AU2015276899A patent/AU2015276899B2/en not_active Ceased
- 2015-06-19 EP EP15809484.7A patent/EP3158086B1/en active Active
- 2015-06-19 EA EA201692497A patent/EA036889B1/ru unknown
- 2015-06-19 JP JP2016573588A patent/JP6684230B2/ja not_active Expired - Fee Related
- 2015-06-19 CN CN201580044280.9A patent/CN106795561B/zh not_active Expired - Fee Related
- 2015-06-19 SG SG11201610610YA patent/SG11201610610YA/en unknown
- 2015-06-19 WO PCT/US2015/036677 patent/WO2015196064A1/en not_active Ceased
- 2015-06-19 SG SG10202007972SA patent/SG10202007972SA/en unknown
- 2015-06-19 BR BR112016029911A patent/BR112016029911A2/pt not_active Application Discontinuation
-
2016
- 2016-12-07 IL IL249443A patent/IL249443B/en unknown
- 2016-12-12 ZA ZA2016/08555A patent/ZA201608555B/en unknown
- 2016-12-15 US US15/380,807 patent/US20170138946A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016029911A2 (pt) | 2017-10-24 |
| EP3158086A1 (en) | 2017-04-26 |
| SG10202007972SA (en) | 2020-10-29 |
| KR20170020463A (ko) | 2017-02-22 |
| AU2015276899B2 (en) | 2021-08-12 |
| SG11201610610YA (en) | 2017-01-27 |
| EP3158086A4 (en) | 2018-01-10 |
| CA2952285A1 (en) | 2015-12-23 |
| EP3158086B1 (en) | 2021-03-24 |
| JP2017525337A (ja) | 2017-09-07 |
| AU2015276899A1 (en) | 2017-01-05 |
| US20170138946A1 (en) | 2017-05-18 |
| ES2870096T3 (es) | 2021-10-26 |
| EA201692497A1 (ru) | 2017-06-30 |
| JP6684230B2 (ja) | 2020-04-22 |
| EA036889B1 (ru) | 2021-01-12 |
| CN106795561A (zh) | 2017-05-31 |
| IL249443A0 (en) | 2017-02-28 |
| MX2016017097A (es) | 2017-05-01 |
| ZA201608555B (en) | 2022-05-25 |
| WO2015196064A1 (en) | 2015-12-23 |
| IL249443B (en) | 2022-05-01 |
| CN106795561B (zh) | 2021-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201692497A1 (ru) | Биомаркеры ответа на ингибиторы ezh2 | |
| SA519401522B1 (ar) | Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات | |
| WO2015172085A3 (en) | Biomarkers for response to pi3k inhibitors | |
| Cerulli | The impact of technological capabilities on invention: An investigation based on country responsiveness scores | |
| MX2017005751A (es) | Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40. | |
| EA201692370A1 (ru) | КОМПОЗИЦИИ иРНК АНГИОТЕНЗИНОГЕНА (AGT) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ | |
| EA201890185A1 (ru) | Способы лечения опосредованных гепсидином нарушений | |
| EA201790802A1 (ru) | Соединения против tnf | |
| MX372986B (es) | Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh) | |
| MX394629B (es) | Método para tratar el cáncer. | |
| MX2016014624A (es) | Metodos para el tratamiento de enfermedad inflamatoria del intestino. | |
| EA201890747A1 (ru) | Способы лечения воспалительных заболеваний | |
| IL253710B (en) | Biomarkers for pancreatic cancer and kits and methods for detecting same | |
| CY1122233T1 (el) | Μεθοδος για την προβλεψη του αποτελεσμaτος μιας θεραπειας με αφλιβερσεπτη ενος ασθενους με υποψια οτι πασχει απο καρκινο | |
| EA201790769A1 (ru) | Определение уровней гликозаминогликанов методом масс-спектрометрии | |
| BR112016016101A2 (pt) | Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos | |
| MX382673B (es) | Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogénica de cáncer colorrectal metastasico. | |
| MX2018016057A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
| MX394355B (es) | Método de tratamiento de meduloblastoma con un inhibidor de ezh2. | |
| EA201792641A1 (ru) | Ингибитор оси igfbp3/tmem219 и диабет | |
| EA201891527A1 (ru) | Композиции и способы обнаружения и лечения рака пищевода | |
| EA201692350A1 (ru) | Биомаркеры легочной гипертензии | |
| MX2016009450A (es) | Ensayo novedoso para detectar periostina humana. | |
| EA201790484A1 (ru) | Производные тетрагидрохинолина в качестве ингибиторов бромодомена | |
| EP4357777A3 (en) | Method for predicting cancer progression by nanomechanical profiling |